Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
NCT00688116
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
45
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumors
Interventions
DRUG:
STA 9090 (ganetespib)
Sponsor
Synta Pharmaceuticals Corp.